22.05
price down icon9.96%   -2.44
pre-market  시장 영업 전:  22.39   0.34   +1.54%
loading
전일 마감가:
$24.49
열려 있는:
$24.31
하루 거래량:
1.24M
Relative Volume:
1.99
시가총액:
$1.68B
수익:
-
순이익/손실:
$-64.16M
주가수익비율:
-17.36
EPS:
-1.2702
순현금흐름:
$-69.06M
1주 성능:
-19.93%
1개월 성능:
-14.73%
6개월 성능:
-40.24%
1년 성능:
-48.43%
1일 변동 폭
Value
$21.93
$24.35
1주일 범위
Value
$21.93
$28.00
52주 변동 폭
Value
$21.93
$46.99

Cg Oncology Inc Stock (CGON) Company Profile

Name
명칭
Cg Oncology Inc
Name
전화
(949) 419-6203
Name
주소
400 SPECTRUM CENTER DRIVE, IRVINE
Name
직원
113
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
CGON's Discussions on Twitter

CGON을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CGON
Cg Oncology Inc
22.05 1.68B 0 -64.16M -69.06M -1.2702
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Cg Oncology Inc Stock (CGON) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-01-07 개시 TD Cowen Buy
2024-10-24 개시 UBS Buy
2024-09-23 개시 RBC Capital Mkts Outperform
2024-08-28 개시 ROTH MKM Buy
2024-06-28 개시 BofA Securities Buy
2024-02-20 개시 Cantor Fitzgerald Overweight
2024-02-20 개시 Goldman Neutral
2024-02-20 개시 Morgan Stanley Overweight
2024-02-14 개시 H.C. Wainwright Buy
모두보기

Cg Oncology Inc 주식(CGON)의 최신 뉴스

pulisher
03:43 AM

Teacher Retirement System of Texas Acquires Shares of 11,927 CG Oncology, Inc. (NASDAQ:CGON) - Defense World

03:43 AM
pulisher
Apr 01, 2025

Relative Strength Alert For CG Oncology - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

CG Oncology (NASDAQ:CGON) Receives “Buy” Rating from HC Wainwright - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

HC Wainwright maintains CG Oncology stock Buy rating, $75 target By Investing.com - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade - Yahoo Finance

Mar 31, 2025
pulisher
Mar 31, 2025

Practice-Changing Bladder Cancer Results: Key BOND-003 Trial Data Revealed at Major Urology Conference - Stock Titan

Mar 31, 2025
pulisher
Mar 30, 2025

CG Oncology announces mixed shelf offering - MSN

Mar 30, 2025
pulisher
Mar 29, 2025

CG Oncology Advances in Bladder Cancer Therapeutics - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

CG Oncology Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

CG Oncology Inc Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

CG Oncology, Inc. SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

CG Oncology Reports 2024 Year End Financial Results And Provides Business Updates - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates - The Manila Times

Mar 28, 2025
pulisher
Mar 28, 2025

Swiss National Bank Has $2.28 Million Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World

Mar 28, 2025
pulisher
Mar 26, 2025

Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? - Insider Monkey

Mar 26, 2025
pulisher
Mar 26, 2025

CG Oncology’s (CGON) Buy Rating Reaffirmed at HC Wainwright - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

H.C. Wainwright maintains CG Oncology buy with $75 target By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

H.C. Wainwright maintains CG Oncology buy with $75 target - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts - Benzinga

Mar 25, 2025
pulisher
Mar 24, 2025

CG Oncology Shares Rise After Reporting Bladder Cancer Drug Durability in Phase 3 Trial - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

Cretostimogene shows promise in bladder cancer study By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund - Endpoints News

Mar 24, 2025
pulisher
Mar 24, 2025

Cretostimogene shows promise in bladder cancer study - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

CG Oncology Reports Promising BOND-003 Data: 75.5% Complete Response Rate for Cretostimogene in Bladder Cancer Treatment - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Breakthrough: Novel Bladder Cancer Drug Shows 75% Response Rate with 28-Month Durability - Stock Titan

Mar 24, 2025
pulisher
Mar 23, 2025

CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Charles Schwab Investment Management Inc. - Defense World

Mar 23, 2025
pulisher
Mar 19, 2025

Bank of New York Mellon Corp Decreases Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON) - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

CG Oncology (CGON) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 18, 2025
pulisher
Mar 16, 2025

CG Oncology (NASDAQ:CGON) Stock Price Up 7.3% – Time to Buy? - Defense World

Mar 16, 2025
pulisher
Mar 16, 2025

11,853 Shares in CG Oncology, Inc. (NASDAQ:CGON) Purchased by Arizona State Retirement System - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

CG Oncology, Inc. (NASDAQ:CGON) Given Average Recommendation of “Buy” by Analysts - The AM Reporter

Mar 15, 2025
pulisher
Mar 15, 2025

CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Mar 15, 2025
pulisher
Mar 13, 2025

Cg Oncology Inc (CGON): A Sitting Duck With -181.74% Upside Potential - Stocks Register

Mar 13, 2025
pulisher
Mar 12, 2025

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates - The Manila Times

Mar 12, 2025
pulisher
Mar 12, 2025

CG Oncology to Present Late-Breaking Abstract and Key Research on Cretostimogene Grenadenorepvec at 40th Annual EAU Congress - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Major Clinical Trial Results: CG Oncology Unveils New Bladder Cancer Treatment Data at European Congress - StockTitan

Mar 12, 2025
pulisher
Mar 09, 2025

CG Oncology (NASDAQ:CGON) Earns Overweight Rating from Morgan Stanley - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

3 Analysts Assess CG Oncology: What You Need To Know - Benzinga

Mar 07, 2025
pulisher
Mar 07, 2025

Oncolytic Adenovirus Market Set to Grow Substantially Through 2032, DelveInsight Projects | CG Oncology, Orca Therapeutics B.V., Syneos Health, DNAtrix, Inc. - Barchart

Mar 07, 2025
pulisher
Mar 07, 2025

Oncolytic Adenovirus Market Set to Grow Substantially Through - openPR

Mar 07, 2025
pulisher
Mar 06, 2025

ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug - Benzinga

Mar 06, 2025
pulisher
Mar 05, 2025

New York State Common Retirement Fund Grows Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Cg Oncology Inc (CGON) is looking forward to a strong quarter - SETE News

Mar 04, 2025
pulisher
Mar 04, 2025

CG Oncology stock hits 52-week low at $24.15 amid challenges - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Rhumbline Advisers - Defense World

Mar 04, 2025
pulisher
Feb 26, 2025

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

Can CG Oncology's CEO Presentation Reveal New Bladder Cancer Treatment Progress? - StockTitan

Feb 26, 2025
pulisher
Feb 25, 2025

CG Oncology Enters Oversold Territory (CGON) - Nasdaq

Feb 25, 2025
pulisher
Feb 25, 2025

CG Oncology stock hits 52-week low at $25.71 amid challenges - Investing.com Canada

Feb 25, 2025
pulisher
Feb 25, 2025

Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now? - Insider Monkey

Feb 25, 2025
pulisher
Feb 24, 2025

IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip

Feb 24, 2025

Cg Oncology Inc (CGON) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
자본화:     |  볼륨(24시간):